Skip to main content

Table 2 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO or high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics

Non-high FeNO and non-high blood eosinophils (n = 200)

High FeNO or high blood eosinophils (n = 200)

p-value

Sex

 n (% non-missing)

200 (100.0)

200 (100.0)

1.0000

 Male

84 (42.0)

84 (42.0)

 

Age

 n (% non-missing)

200 (100.0)

200 (100.0)

0.9223

 Mean (SD)

51.7 (13.1)

51.6 (13.2)

 

 Median (IQR)

54.0 (18.5)

53.0 (19.5)

 

Age group

 n (% non-missing)

200 (100.0)

200 (100.0)

0.4289

 Under 35

24 (12.0)

25 (12.5)

 

 35–65

150 (75.0)

140 (70.0)

 

 66–80

26 (13.0)

35 (17.5)

 

Smoking status

 n (% non-missing)

200 (100.0)

200 (100.0)

1.0000

 Non-smoker

73 (36.5)

73 (36.5)

 

 Ex-smoker

23 (11.5)

23 (11.5)

 

 Current smoker

71 (35.5)

71 (35.5)

 

BMI

 n (% non-missing)

189 (94.5)

191 (95.5)

0.1025

 Mean (SD)

30.0 (6.9)

29.1 (7.0)

 

 Median (IQR)

28.7 (8.1)

27.8 (7.9)

 

Active eczema diagnosisa

 n (% non-missing)

200 (100.0)

200 (100.0)

0.3347

 Yes

7 (3.5)

11 (5.5)

 

Active rhinitis diagnosisa

 n (% non-missing)

200 (100.0)

200 (100.0)

0.1056

 Yes

55 (27.5)

70 (35.0)

 

Eczema diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.1284

 Yes

54 (27.0)

68 (34.0)

 

Rhinitis diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.0858

 Yes

77 (38.5)

94 (47.0)

 

IHD diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

1.0000

 Yes

9 (4.5)

9 (4.5)

 

Heart failure diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.3167

 Yes

0 (0.0)

1 (0.5)

 

Hypertension diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.0592

 Yes

55 (27.5)

39 (19.5)

 

Diabetes diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.8630

 Yes

19 (9.5)

18 (9.0)

 

GERD active diagnosis

 n (% non-missing)

200 (100.0)

200 (100.0)

0.0630

 Yes

35 (17.5)

22 (11.0)

 

Predicted peak flow

 n (% non-missing)

105 (52.5)

110 (55.0)

0.7422

 Mean (SD)

516.0 (73.2)

519.4 (75.8)

 

 Median (IQR)

485.8 (134.7)

487.6 (137.8)

 

ICS/LABA prescriptions per patient

 n (% non-missing)

200 (100.0)

200 (100.0)

0.4736

 Mean (SD)

4.1 (4.0)

4.1 (3.7)

 

 Median (IQR)

3.0 (5.0)

3.5 (5.0)

 

Mono ICS prescriptions per patient

 n (% non-missing)

200 (100.0)

200 (100.0)

0.0112

 Mean (SD)

1.4 (2.7)

0.6 (1.6)

 

 Median (IQR)

0.0 (1.0)

0.0 (0.0)

 

Mean daily SABA dosage (µg)

 n (% non-missing)

200 (100.0)

200 (100.0)

0.2808

 < 100

67 (33.5)

83 (41.5)

 

 100–200

58 (29.0)

47 (23.5)

 

 201–400

45 (22.5)

47 (23.5)

 

 > 400

30 (15.0)

23 (11.5)

 

ICS adherenceb

 n (% non-missing)

200 (100.0)

200 (100.0)

0.1931

 Mean (SD)

72.2 (72.7)

63.3 (53.3)

 

 Median (IQR)

61.7 (64.4)

52.0 (61.7)

 
  1. All values in table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us